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Abstract. Human glioblastomas are characterized by frequent 
DNA amplifications most often at chromosome regions 7p11.2 
and 12q13-15. Although amplification is a well-known hall-
mark of glioblastoma genetics the function of most amplified 
genes in glioblastoma biology is not understood. Previously, 
we cloned Ku70-binding protein 3 (KUB3) from the amplified 
domain at 12q13-15. Here, we report that glioblastoma cell 
cultures with endogenous KUB3 gene amplification and with 
elevated KUB3 protein expression show an efficient double-
strand break (DSB) repair after being irradiated with 1 Gy. 
A significantly less efficient DSB repair was found in glioma 
cell cultures without KUB3 amplification and expression. 
Furthermore, we found that a siRNA-mediated reduction of the 
endogenous KUB3 expression in glioblastoma cells resulted 
in a reduction of the repair efficiency. HeLa cells transfected 
with KUB3 showed an increased DSB repair in comparison to 
untreated HeLa cells. In addition, KUB3 seems to influence 
DSB efficiency via the DNA-PK-dependent repair pathway as 
shown by simultaneous inhibition of KUB3 and DNA-PK. The 
data provide the first evidence for a link between the level of 
KUB3 amplification and expression in glioma and DSB repair 
efficiency.
Introduction
DNA amplification frequently occurs in human tumors but 
very rarely in normal human cells. Glioblastoma multiforme 
(GBM) that are characterized by a severe genomic instability 
show frequent amplifications predominantly as double minute 
chromosomes and less frequently as homogeneously staining 
region. DNA amplifications in GBM are found most often at 
7p11.2 and 12q13-15 (1). Previously, we cloned several genes 
from the amplified domain at 12q13-15 including GAS41 
(glioma expressed sequence), CYP27B1 and GAS16 by 
microdissection-mediated cDNA capture (2-5). GAS16 results 
from an alternative splicing process of the gene KUB3 coding 
for Ku70-binding protein 3 (KUB3). KUB3 was found to 
bind Ku70 by yeast two-hybrid screening (6). Ku70 has been 
associated with the DNA-dependent protein kinase (DNA-PK) 
complex involved in double-strand break repair. DNA double-
strand breaks (DSBs) are considered to be the most relevant 
DNA lesions. Unrepaired DSBs can cause cell death and 
misrepaired DSBs may lead to chromosomal translocations 
and genomic instability that is a hallmark of GBM (7-9).
There are two major DSB repair pathways. The homologous 
recombination (HR) repairs the break using an undamaged 
homologous chromatid or chromosome, whereas the non-
homologous end-joining (NHEJ) ligates the DNA end directly 
(10). The main proteins required for NHEJ in mammalian cells 
are the DNA-dependent protein kinase (DNA-PK) formed 
by the Ku70/Ku80 heterodimer and the catalytic subunit 
DNA-PKcs in association with Artemis and the XRCC4/
Ligase IV/Cernunnos-XLF complex. Ku and DNA-PKcs 
components are necessary to load this complex to the site of 
the break (11,12), whereas the XRCC4/Ligase IV complex is 
responsible for the ligation step (13,14).
Analyzing >100 primary glioma we found KUB3 also 
termed XRCC6BP1 (X-ray repair cross-complementation 
group 6 binding protein 1) to be amplified in 14% of GBM, 30% 
of anaplastic astrocytoma and 3% of pilocytic astrocytoma. 
Northern blot analysis of GBM showed a correlation between 
KUB3 amplification and overexpression. Amplification of 
KUB3 was associated with significantly shorter survival time 
as shown by our experimental data and by in silico analysis of 
185 GBM samples from the TCGA data collection (15).
With the frequent amplification of KUB3 in glioma, 
especially in higher-grade glioma and with its association to 
DNA repair pathways, overexpression of KUB3 likely confers 
properties to growth advantage in GBM cells. This idea is 
consistent with the prolonged survival of patients with glioma 
without KUB3 amplification in comparison to patients with 
KUB3 amplification. Here, we set out to analyze the interrela-
tionship between KUB3 amplification, KUB3 expression and 
DSB-repair in glioma. Specifically, we address the following 
questions. Do glioma with a higher KUB3 (XRCC6BP1) 
amplification show a more efficient DSB repair than glioma 
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with a lesser or none KUB3 amplification? Does the endog-
enous expression level of KUB3 correlate with the DSB repair 
efficiency in glioma? Does induced reduction or induced 
increase of KUB3 expression affect the DSB repair efficiency? 
Does KUB3 act in a DNA-PK dependent manner? Overall, the 
study aims to contribute to understanding the cellular effects 
of KUB3 amplification in human glioma.
Materials and methods
Ethics statement. Glioblastoma tissue samples were obtained 
from the Neurosurgery Department of Saarland University 
(Homburg, Germany) with patient's written informed consent. 
The study was approved by the local ethics committee of the 
‘Ärztekammer des Saarlandes’ on September 2001 for glioma 
study (Ethik-Komm./Ls).
Cells and cell lines. Normal human astrocytes were obtained 
from CellSystems and maintained in ABM (astrocyte basal 
medium) without L-glutamine (Clonetics, Cambrex Bio 
Science, Walkersville, MD, USA). The glioblastoma cell lines 
TX3868 and TX3095 were established at our institute after 
xenografting. The glioblastoma cell cultures H346 and H385 
and the astrocytoma cell culture T6468 were established at 
our institute. The different glioma cell lines and cultures were 
grown in DMEM supplemented with 10% fetal calf serum 
(PAA), 100 U/ml of penicillin and 100 µg/ml of streptavidin 
(2,16,17). HeLa cells (ATCC) were maintained in DMEM 
containing 10% fetal calf serum (Biochrom AG, Berlin, 
Germany).
Brain tumor samples. Tissues of 15 glioblastoma multiforme 
(WHO grade IV) were obtained from the Neurosurgery 
Department of Saarland University (Homburg, Germany) with 
patient's written informed consent. The samples were frozen in 
liquid nitrogen immediately after resection and stored at -80˚C 
until use.
Cell culture, treatment and X-irradiation. Cells were grown 
on cover slips in a humidified 5% CO2 atmosphere at 37˚C 
in DMEM supplemented with 10% fetal bovine serum and 
1% antibiotics (10,000 U/ml penicillin and 10,000 µg/ml strep-
tomycin). Cells were irradiated with X-rays in the exponential 
growth phase at room temperature in cell culture medium. All 
experiments were performed by irradiating cell cultures with 
95 kV and 25 mA, with a 1.3-mm aluminium filter and a dose 
of 1 Gy/min (as determined by chemical dosimetry). NU7026 
(KuDos Pharmaceuticals, Cambridge, UK) (10 µM) was 
added 1 h prior to irradiation and maintained in the medium 
post irradiation.
Transfection. For transfection, 2 µg plasmid-DNA per well 
was used. Plasmid-DNA was complexed at a ratio of 2 µg 
DNA/5 µl Lipofectamine 2000 (Invitrogen, Carlsbad, CA, 
USA). Plasmid-DNA and Lipofectamine 2000 were diluted 
in OPTI-MEM medium (Gibco) and incubated for 5 min at 
room temperature, followed by complexing and incubation for 
20 min. No serum and antibiotics were used in the transfec-
tion mixture. After transfection cells were stored at 37˚C and 
5% CO2 for 24 or 48 h.
siRNA. The Silencer® pre-designed siRNA (Ambion) used for 
silencing the KUB3 expression consisted of 21 bp duplexes 
complementary to a unique sequence of the target gene. 
KUB3-siRNA (CCUUAGUGGAGACUGCUCA) showed an 
effective silencing in KUB3 expression in TX3868 cells. As a 
negative control, a non-silencing siRNA duplex (UUCUCCGA 
ACGUGUCACGUdTdT), fluorescent (3'-fluorescein-conju-
gated) and non-fluorescent was used (Qiagen). Transfections of 
cells with these siRNAs were done by using Lipofectamine 2000 
(Invitrogen, Carlsbad, CA, USA) at a ratio of 1.3 µg siRNA/6.5 µl 
Lipofectamine 2000.
Antibodies. A rabbit anti-KUB3 antibody was raised against 
KUB3 N-terminus (DERRRGPAAGEQLQQQHVS) and 
was used at a 1:100 dilution for western blot analysis. The 
following antibodies were used at the indicated concentra-
tion: mouse monoclonal anti-γ-H2AX antibody (Upstate 
Biotechnology) at a 1:200 dilution for immunofluorescence; 
mouse monoclonal anti-β-actin (clone AC-15) (Sigma) 
at a 1:10,000 dilution for western blotting. Horseradish 
peroxidase-conjugated secondary antibodies were purchased 
from Jackson ImmunoResearch Laboratories (Dianova): goat 
anti-rabbit IgG (dilution 1:20,000) and sheep anti-mouse IgG 
(dilution 1:30,000). The fluorescent secondary antibody Alexa 
Fluor 488-conjugated goat anti-mouse (MoBiTec) was used at 
a 1:500 dilution.
Immunofluorescence. Cells grown on cover slips were fixed 
in 100% methanol (-20˚C) for 30 min, permeabilized in 
acetone (-20˚C) for 1 min and washed three times for 10 min 
in 1% FCS/PBS. Samples were incubated with primary anti-
body in 1% FCS/PBS at room temperature for 1 h, washed 
in 1% FCS/PBS three times for 10 min and incubated with 
secondary antibody at room temperature for 1 h. Cells were 
washed in PBS four times for 10 min and mounted using 
Vectashield mounting medium containing 4,6-diaminodino-
2-phenylindole (Vector Laboratories). In a single experiment, 
cell counting was performed until ≥40 cells and 40 foci were 
registered per sample. Each data-point represents three inde-
pendent experiments. Error bars represent the standard error 
of the mean (SEM) between the different experiments.
Tumor cell lysates. Approximately 0.5 g tumor tissue was 
homogenized in 2.5 ml sample buffer [5.8% SDS (w/v), 120 mM 
Tris pH 6.8; 9.5% β-mercaptoethanol (v/v), 9.5% glycerol (v/v)] 
supplemented with protease inhibitor cocktail (Complete Mini 
EDTA free, Roche). After an incubation time of 10 min at room 
temperature the supernatant was collected by centrifuging at 
3,000 g at 4˚C for 20 min. This solution was homogenized and 
centrifuged at 3,000 g at 4˚C for 20 min. The samples were 
boiled at 98˚C for 5 min and then centrifuged at 12,000 g at 
4˚C for 30 min to remove any precipitate.
Western blotting. Whole cell extracts of treated or mock-treated 
cells were obtained by direct lysis in lysis buffer (50 mM 
Tris-HCl pH 8.0, 150 mM NaCl, 1% NP40) supplemented 
with protease inhibitor cocktail (Complete Mini EDTA-free, 
Roche). Concentrated loading sample buffer was added for 
1X final concentration in all fractions and the samples were 
boiled for 5 min. Equal aliquots of each sample were separated 
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on SDS-PAGE (12%) and blotted onto Hybond-P membrane 
(Amersham). Human brain whole cell lysate (Abcam) was used 
as control. Membranes were blocked with Tris-buffered saline 
(TBS) containing 5% skim milk and 0.05% Tween-20 (Sigma) 
at 4˚C overnight. Immunostaining was performed in the 
same buffer using appropriate first and secondary antibodies. 
Protein detection was performed using the ECL Plus detection 
kit (Amersham) according to the manufacturer's instructions.
Results
KUB3 is known to be frequently amplified and/or overex-
pressed as mRNA in GBM, however, no evidence for KUB3 
protein overexpression in GBM tissues has been reported. 
Using western blotting we analyzed cell lysates from 14 GBM 
tissues to confirm KUB3 overexpression in GBM. We found 
strong KUB3 protein expression in 10 GBM, weak expression 
in 3 cases and lack of expression in one GBM and in normal 
brain that served as negative control (Fig. 1). These western 
blotting data are in agreement with the frequent mRNA 
overexpression in GBM. Although overexpression of KUB3 
is more frequent than KUB3 amplification, KUB3 overexpres-
sion appears to be mediated not only by DNA amplification but 
also by other mechanisms. The first hint towards the function 
of KUB3 stems from Boothmann and colleagues that found 
binding to Ku70 by yeast-two-hybrid studies. We confirmed 
this binding by co-immuno precipitation of FLAG-KUB3 and 
Ku70 protein using COS1 cells (data not shown).
Next, we examined whether KUB3 amplification can be 
associated with the DSB repair efficiency in GBM. We derived 
cell cultures from two primary GBMs (H346 and H385), two 
xenografts (TX3868 and TX3095) and a WHO II astrocytoma 
(T6468). These selected cell cultures showed different levels 
of KUB3 amplification. The amplification level was highest for 
TX3868, followed by H346 and TX3095. No amplification of 
KUB3 was found for H385 and for T6468 (Fig. 2B).
Figure 1. Western blot analysis of endogenous KUB3 protein in different glioblastomas and in normal brain. Total protein extract (30 µg) was separated by 
SDS-PAGE. The membrane was immunostained by anti-KUB3. β-actin staining confirmed equal loading. Arrows indicate KUB3 at 32 kDa.
Figure 2. (A) Correlation between KUB3 amplification and DSB repair efficiency in glioma derived cell cultures and normal human astrocytes. Following 
radiation with 1 Gy, γ-H2AX foci were counted in glioblastoma cell lines TX3095, TX3868, H346 and H385, in astrocytoma (WHO II) T6468 and in normal 
human astrocytes (NHA). Percentage of remaining γ-H2AX foci (indirect readout for DSBs) is indicated on the y-axis. The repair time is plotted on the x-axis. 
(B) Expression and amplification status of glioma derived cell lines, normal brain and normal human astrocytes. Total protein extract (30 µg) was separated by 
SDS-PAGE. The membrane was immunostained with anti-KUB3. β-actin staining confirmed equal loading. Arrows indicate KUB3 at 32 kDa.
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The level of amplification mirrors the level of KUB3 
expression as shown by western blotting with a polyclonal 
KUB3 antibody. Cell cultures with high KUB3 amplification 
show strong KUB3 expression whereas low-level KUB3 ampli-
fication was associated with a very weak KUB3 expression 
(Fig. 2B). Likewise, normal brain that was used as reference 
for western blotting showed a very weak KUB3 expression. 
From GBM culture H385 we did not obtain sufficient protein.
Each of the cell cultures was irradiated with 1 Gy. As control 
we used normal human astrocytes (NHA). Between 15 min and 
8 h after radiation, we counted the number of DSBs that were 
visualized as γ-H2AX foci (Fig. 2A). Throughout this time 
period low numbers of foci were found in TX3868, H346 and 
TX3095. These data indicate an efficient double-strand break 
repair in GBM cell cultures that harbour an amplified KUB3 
gene and show elevated KUB3 protein expression. The most 
efficient repair was found in the GBM cell cultures with the 
highest amplification and expression level of KUB3 namely 
TX3868 and H346. After 8 h following radiation close to 85% 
of the DSBs were repaired.
Less efficient repair was found in the GBM cell line H385 
that showed no amplification and in the astrocytoma WHO II 
derived cell line T6468 that shows neither amplification nor 
expression. We found the least efficient DNA repair in normal 
human astrocytes. DSB repair in TX3868 cells with high 
KUB3 amplification and expression is approximately twice 
as efficient as DSB repair in normal astrocytes that repaired 
50% of the DSBs after 8 h. Each experiment was repeated 
three times. Except for the NHA cells we found very small 
error bars for each cell culture. The results are indicative of a 
general correlation between the level of KUB3 amplification 
and expression in glioma and the repair efficiency of DSBs 
(Fig. 2).
To provide functional evidence for the observed correlation, 
we compared untreated HeLa cells with HeLa cells transfected 
with KUB3. While KUB3 was barely visible in untreated HeLa 
cells, transfected cells showed a KUB3 signal in western blot 
analysis (Fig. 3). Both transfected and untransfected HeLa 
cells were irradiated with 1 Gy and analyzed for the number 
of γ-H2AX foci. HeLa cells transfected with KUB3 showed 
less foci indicating a better double-strand break repair than 
untreated HeLa cells (Fig. 3). As for the analysis of glioma 
cell cultures, each experiment was repeated three times and 
the results were highly reproducible. The relatively moderate 
improvement of the DSB repair efficiency in transfected 
HeLa cells may be explained by the moderate expression of 
the KUB3 protein found upon transfection. This expression is 
considerably lower than the expression found in glioblastoma 
cells TX3095 and TX3868 that also showed a significantly 
more efficient repair efficiency of DSBs.
To further test the effect of altered KUB3 expression on 
repair efficiency we reduced the high endogenous KUB3 
expression in TX3868 cells by transfecting these cells with 
Figure 3. DSB repair efficiency in transfected HeLa cells that overexpress KUB3 and in HeLa cells with low endogenous KUB3 expression. KUB3 expression 
was demonstrated by immunostaining with anti-KUB3. β-actin staining confirmed equal loading. Following radiation with 1 Gy, γ-H2AX foci were counted 
in HeLa cells. Percentage of remaining γ-H2AX foci (indirect readout for DSBs) is indicated on the y-axis. The repair time is plotted on the x-axis. Error bars 
represent the SEM of the analysis of 40 cells in three different experiments.
Figure 4. DSB repair efficiency in TX3868 and TX3868 cells transfected 
with KUB3 siRNA. KUB3 expression was demonstrated by immunostaining 
with anti-KUB3. β-actin staining confirmed equal loading. Following 
radiation with 1 Gy, γ-H2AX foci were counted in HeLa cells. Percentage 
of remaining γ-H2AX foci (indirect readout for DSBs) is indicated on the 
y-axis. The repair time is plotted on the x-axis. Error bars represent the SEM 
of the analysis of 40 cells in three different experiments.
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KUB3 siRNA. The expression level was reduced significantly 
as shown in Fig. 4. We also found a significantly increased 
number of γ-H2AX foci in TX3868 cells treated with KUB3 
siRNA in comparison to untreated TX3868 cells (Fig. 4). 
Four hours after radiation >65% of the DSBs were repaired 
in untreated TX3868 cells as compared to 40% in TX3868 
cells treated by KUB3 siRNA. Similar ratios were found 
after 8 h with >75% of repaired DSBs in untreated TX3868 
cells and 50% in treated TX3868 cells. In summary, both the 
transfection with KUB3 and the treatment with KUB3 siRNA 
demonstrates that altered KUB3 expression impact the repair 
efficiency.
Binding of KUB3 to Ku70 suggests that KUB3 exerts 
its effect on DSB repair via DNA-PK. To clarify whether 
the observed effects of KUB3 on double-strand repair are 
dependent or independent of DNA-PK activity, we inhibited 
DNA-PK activity by NU7026 in the cell cultures with high 
KUB3 amplification and expression and with elevated repair 
efficiency. Specifically, we analyzed TX3095, TX3868 and 
H346 cells. In all three cell cultures we found reduced double-
strand repair efficiency after NU7026 treatment. The extent 
of reduction was similar in TX3868 and TX3095. TX3868 
cells that had the highest repair efficiency prior to inhibition 
of DNA-PK, showed also the highest repair efficiency after the 
treatment as compared to the cell cultures TX3095 and H346. 
TX3095 cells with the lowest repair efficiency maintained this 
low efficiency after treatment as compared to TX3868. The 
most significant reduction in repair efficiency was found for 
H346 (Fig. 5).
Discussion
Although frequent gene amplifications in glioma are well 
established, we know little about the specific function of most 
amplified genes for the tumor phenotype. Here, we show that 
both the amplification level and the expression level of KUB3 
are associated with the efficiency of DSBs in glioblastoma. 
KUB3 seems to influence DSB repair efficiency via DNA-PK 
dependent repair pathway.
An increased DSB repair as a result of a KUB3 amplifi-
cation may be part of the mechanisms that contribute to the 
radiation-resistant phenotype frequently found for glioblas-
toma cells. Circumstantial evidence for such a link can be 
derived from various studies. A comparison of transcriptional 
changes in two glioblastoma cell lines with different degrees 
of radiation-sensitivity identified a larger number of genes 
known to be involved in DSB repair (18). One of the genes 
identified as differentially expressed in the two cell lines was 
G22P1 (Ku70). As shown in a clonogenic assay tumors with a 
low frequency of Ku70 immunopositive cells are radiosensi-
tive (19).
Besides Ku expression, DNA-PK expression was 
also related to the radiation-resistance of tumor cells. 
Overexpression of the catalytic subunit DNA-PKcs was 
reported for various human cancers (20-24). Inhibition of the 
function of the DNA-PK sensitized tumor cells to radiation 
as shown for cervical cancer (25). A study on oral squamous 
cell carcinoma showed that upregulation of DNA-PK complex 
protein following radiation treatment correlates to radiation 
resistance (23). There is functional evidence for a causative 
role of DNA-PKcs in the radiation-resistant phenotype of 
glioblastoma. While glioblastoma cell line MO59J that lacks 
DNA-PKcs is radiosensitive, transfection of DNA-PKcs in 
MO59J reverses the radiation-sensitive phenotype (26,27). 
Inhibition of the DNA-PK expression also enhances the sensi-
tivity of cells to chemotherapeutic agents (28).
One has, however, to be cautious to prematurely propose 
a simple link between radiation-resistance and double-strand 
break repair efficiency. Recent data demonstrate inefficient 
repair of double-strand breaks in several radiation-resistant 
glioblastoma cell lines (29). Such an inefficient repair is 
possible due to the genetic background of a tumor, specifically 
due to TP53 mutations that are frequently found in glioblas-
toma (30).
In addition to the radiation-resistance of tumor cells, 
patients' overall survival has been associated with DSB repair. 
Tumors with a low percentage of Ku70 positive cells have 
been associated with a significantly higher overall patients' 
Figure 5. DSB repair efficiency in TX3095, TX3868 and H346 cells analyzed in the presence of DNA-PK inhibitor NU7026. Following radiation with 1 Gy, 
γ-H2AX foci were counted in NU7026 treated glioblastoma cell lines TX3095, TX3868 and H346. Results from the untreated glioblastoma cell lines were 
included in this figure for better visualization of the differences between DSB repair with and without NU7026. Percentage of remaining γ-H2AX foci, indirect 
readout for DSBs is indicated on the y-axis. The repair time is plotted on the x-axis.
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survival. This association was also found for Ku80, but did not 
reach significance. In addition, expression of Ku70 was identi-
fied as possible prognostic factor for the survival for cervix 
carcinoma patients undergoing radiotherapy (19). Strong 
evidence for an association between DNA repair and survival 
of glioma patients stems from studies on DNA repair enzyme 
O6-methyl-guanine DNA methyltransferase (MGMT) and 
the alkylating agent temozolomide (TMZ). MGMT that is a 
central enzyme for DNA repair, removes mutagenic adducts 
from O6-guanine in DNA. Silencing MGMT by methylating 
its promoter, has been associated with improved survival rates 
of glioblastoma patients that were treated with TMZ (31,32). 
Likewise, downregulation of MGMT by interleukin-24 helps 
to overcome TMZ resistance (33). By contrast, MGMT expres-
sion predicts a shorter overall survival of glioblastoma patients 
treated by TMZ (31). This observation is in good agreement 
with the observation that glioma patients without KUB3 
amplification show a prolonged survival in comparison to 
patients with KUB3 amplification (15).
While KUB3 is involved in DSB repair, it does not seem to 
play a role in the V(D)J-joining (data not shown). Other proteins 
of DNA-PK, including DNA-PKcs, Ku70/80 heterodimer, 
XRCC4, ligase 4, artemis and cernunnos-XLF, all of which 
known be involved in non-homologous end joining were also 
found to be involved in the V(D)J recombination (13,14,34-42). 
The lack of any of these proteins results in a SCID phenotype 
due to the inability to generate V(D)J joins (43,44). Since our 
preliminary results do not indicate an involvement of KUB3 
in V(D)J recombination, interaction of KUB3 with DNA-PK 
may be different from the known interactions of the aforemen-
tioned repair genes. Possibly, KUB3 is not part of the DNA-PK 
complex but may only exert a regulatory function.
In conclusion, we propose that KUB3 amplification contrib-
utes to the radiation-resistant phenotype of glioblastoma and 
impact survival of glioblastoma patients. While our previous 
study demonstrated an association between KUB3 amplifica-
tion and shortened survival of glioblastoma patients and this 
study analyzed the role of KUB3 in DSB repair, future studies 
are required to establish a role of KUB3 for the radiation-
resistant phenotype of glioblastoma cells.
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